Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas

Maria Moksnes Bjaanæs, Ann Rita Halvorsen, Steinar Solberg, Lars Jørgensen, Tommaso A. Dragani, Antonella Galvan, Francesca Colombo, Marco Anderlini, Ugo Pastorino, Elin Kure, Anne Lise Børresen-Dale, Odd Terje Brustugun, Åslaug Helland

Research output: Contribution to journalArticle

Abstract

The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesis by regulating gene expression at the post-transcriptional level. In this project, we have studied the microRNA expression of lung adenocarcinomas and corresponding normal lung tissue and correlated the expression with clinical data and EGFR- and KRAS-mutational status. Agilent microarrays have been used, examining microRNA expression in 154 surgically resected lung adenocarcinomas and 20 corresponding normal lung tissue samples. Findings were confirmed by RT-qPCR in the same cohort and in an independent cohort of 103 lung cancer patients. EGFR and KRAS mutation analyses were also performed. 129 microRNAs were significantly differentially expressed in lung adenocarcinomas compared with normal lung tissue, and 17 microRNAs were differentially expressed between EGFR-mutated and EGFR wildtype tumors. We identified microRNAs associated with time to progression. We have identified several aberrantly expressed microRNAs that discriminate lung adenocarcinomas from normal lung tissue, and hence may be potential biomarkers for early detection. We have found microRNAs that are differentially expressed between EGFR-mutated and EGFR wildtype lung adenocarcinomas, suggesting that microRNAs can be used as molecular biomarkers in classification. We hypothesize that microRNA expression can be used as biomarkers for clinical course.

Original languageEnglish
Pages (from-to)1812-1821
Number of pages10
JournalInternational Journal of Cancer
Volume135
Issue number8
DOIs
Publication statusPublished - Oct 15 2014

Fingerprint

MicroRNAs
Lung Neoplasms
Biomarkers
Lung
Adenocarcinoma of lung
Biological Phenomena
Mutation
Epigenomics
Carcinogenesis
Gene Expression

Keywords

  • EGFR
  • KRAS
  • lung cancer
  • microRNA
  • survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bjaanæs, M. M., Halvorsen, A. R., Solberg, S., Jørgensen, L., Dragani, T. A., Galvan, A., ... Helland, Å. (2014). Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas. International Journal of Cancer, 135(8), 1812-1821. https://doi.org/10.1002/ijc.28828

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas. / Bjaanæs, Maria Moksnes; Halvorsen, Ann Rita; Solberg, Steinar; Jørgensen, Lars; Dragani, Tommaso A.; Galvan, Antonella; Colombo, Francesca; Anderlini, Marco; Pastorino, Ugo; Kure, Elin; Børresen-Dale, Anne Lise; Brustugun, Odd Terje; Helland, Åslaug.

In: International Journal of Cancer, Vol. 135, No. 8, 15.10.2014, p. 1812-1821.

Research output: Contribution to journalArticle

Bjaanæs, MM, Halvorsen, AR, Solberg, S, Jørgensen, L, Dragani, TA, Galvan, A, Colombo, F, Anderlini, M, Pastorino, U, Kure, E, Børresen-Dale, AL, Brustugun, OT & Helland, Å 2014, 'Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas', International Journal of Cancer, vol. 135, no. 8, pp. 1812-1821. https://doi.org/10.1002/ijc.28828
Bjaanæs MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A et al. Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas. International Journal of Cancer. 2014 Oct 15;135(8):1812-1821. https://doi.org/10.1002/ijc.28828
Bjaanæs, Maria Moksnes ; Halvorsen, Ann Rita ; Solberg, Steinar ; Jørgensen, Lars ; Dragani, Tommaso A. ; Galvan, Antonella ; Colombo, Francesca ; Anderlini, Marco ; Pastorino, Ugo ; Kure, Elin ; Børresen-Dale, Anne Lise ; Brustugun, Odd Terje ; Helland, Åslaug. / Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas. In: International Journal of Cancer. 2014 ; Vol. 135, No. 8. pp. 1812-1821.
@article{014764a4bc8141e3b0add9ca1b4821ea,
title = "Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas",
abstract = "The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesis by regulating gene expression at the post-transcriptional level. In this project, we have studied the microRNA expression of lung adenocarcinomas and corresponding normal lung tissue and correlated the expression with clinical data and EGFR- and KRAS-mutational status. Agilent microarrays have been used, examining microRNA expression in 154 surgically resected lung adenocarcinomas and 20 corresponding normal lung tissue samples. Findings were confirmed by RT-qPCR in the same cohort and in an independent cohort of 103 lung cancer patients. EGFR and KRAS mutation analyses were also performed. 129 microRNAs were significantly differentially expressed in lung adenocarcinomas compared with normal lung tissue, and 17 microRNAs were differentially expressed between EGFR-mutated and EGFR wildtype tumors. We identified microRNAs associated with time to progression. We have identified several aberrantly expressed microRNAs that discriminate lung adenocarcinomas from normal lung tissue, and hence may be potential biomarkers for early detection. We have found microRNAs that are differentially expressed between EGFR-mutated and EGFR wildtype lung adenocarcinomas, suggesting that microRNAs can be used as molecular biomarkers in classification. We hypothesize that microRNA expression can be used as biomarkers for clinical course.",
keywords = "EGFR, KRAS, lung cancer, microRNA, survival",
author = "Bjaan{\ae}s, {Maria Moksnes} and Halvorsen, {Ann Rita} and Steinar Solberg and Lars J{\o}rgensen and Dragani, {Tommaso A.} and Antonella Galvan and Francesca Colombo and Marco Anderlini and Ugo Pastorino and Elin Kure and B{\o}rresen-Dale, {Anne Lise} and Brustugun, {Odd Terje} and {\AA}slaug Helland",
year = "2014",
month = "10",
day = "15",
doi = "10.1002/ijc.28828",
language = "English",
volume = "135",
pages = "1812--1821",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas

AU - Bjaanæs, Maria Moksnes

AU - Halvorsen, Ann Rita

AU - Solberg, Steinar

AU - Jørgensen, Lars

AU - Dragani, Tommaso A.

AU - Galvan, Antonella

AU - Colombo, Francesca

AU - Anderlini, Marco

AU - Pastorino, Ugo

AU - Kure, Elin

AU - Børresen-Dale, Anne Lise

AU - Brustugun, Odd Terje

AU - Helland, Åslaug

PY - 2014/10/15

Y1 - 2014/10/15

N2 - The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesis by regulating gene expression at the post-transcriptional level. In this project, we have studied the microRNA expression of lung adenocarcinomas and corresponding normal lung tissue and correlated the expression with clinical data and EGFR- and KRAS-mutational status. Agilent microarrays have been used, examining microRNA expression in 154 surgically resected lung adenocarcinomas and 20 corresponding normal lung tissue samples. Findings were confirmed by RT-qPCR in the same cohort and in an independent cohort of 103 lung cancer patients. EGFR and KRAS mutation analyses were also performed. 129 microRNAs were significantly differentially expressed in lung adenocarcinomas compared with normal lung tissue, and 17 microRNAs were differentially expressed between EGFR-mutated and EGFR wildtype tumors. We identified microRNAs associated with time to progression. We have identified several aberrantly expressed microRNAs that discriminate lung adenocarcinomas from normal lung tissue, and hence may be potential biomarkers for early detection. We have found microRNAs that are differentially expressed between EGFR-mutated and EGFR wildtype lung adenocarcinomas, suggesting that microRNAs can be used as molecular biomarkers in classification. We hypothesize that microRNA expression can be used as biomarkers for clinical course.

AB - The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesis by regulating gene expression at the post-transcriptional level. In this project, we have studied the microRNA expression of lung adenocarcinomas and corresponding normal lung tissue and correlated the expression with clinical data and EGFR- and KRAS-mutational status. Agilent microarrays have been used, examining microRNA expression in 154 surgically resected lung adenocarcinomas and 20 corresponding normal lung tissue samples. Findings were confirmed by RT-qPCR in the same cohort and in an independent cohort of 103 lung cancer patients. EGFR and KRAS mutation analyses were also performed. 129 microRNAs were significantly differentially expressed in lung adenocarcinomas compared with normal lung tissue, and 17 microRNAs were differentially expressed between EGFR-mutated and EGFR wildtype tumors. We identified microRNAs associated with time to progression. We have identified several aberrantly expressed microRNAs that discriminate lung adenocarcinomas from normal lung tissue, and hence may be potential biomarkers for early detection. We have found microRNAs that are differentially expressed between EGFR-mutated and EGFR wildtype lung adenocarcinomas, suggesting that microRNAs can be used as molecular biomarkers in classification. We hypothesize that microRNA expression can be used as biomarkers for clinical course.

KW - EGFR

KW - KRAS

KW - lung cancer

KW - microRNA

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84905754808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905754808&partnerID=8YFLogxK

U2 - 10.1002/ijc.28828

DO - 10.1002/ijc.28828

M3 - Article

C2 - 24599520

AN - SCOPUS:84905754808

VL - 135

SP - 1812

EP - 1821

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -